PL2081571T3 - Mieszane substancje antagonistyczne ORL 1/µ do zwalczania bólów - Google Patents

Mieszane substancje antagonistyczne ORL 1/µ do zwalczania bólów

Info

Publication number
PL2081571T3
PL2081571T3 PL07818462T PL07818462T PL2081571T3 PL 2081571 T3 PL2081571 T3 PL 2081571T3 PL 07818462 T PL07818462 T PL 07818462T PL 07818462 T PL07818462 T PL 07818462T PL 2081571 T3 PL2081571 T3 PL 2081571T3
Authority
PL
Poland
Prior art keywords
orl1
receptor
agonist
pain
agonists
Prior art date
Application number
PL07818462T
Other languages
English (en)
Inventor
Klaus Linz
Babette-Yvonne Kögel
Wolfgang Schröder
Thomas Christoph
Vry Jean De
Elmar Friderichs
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL2081571T3 publication Critical patent/PL2081571T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07818462T 2006-09-29 2007-09-26 Mieszane substancje antagonistyczne ORL 1/µ do zwalczania bólów PL2081571T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006046745A DE102006046745A1 (de) 2006-09-29 2006-09-29 Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
EP07818462A EP2081571B1 (de) 2006-09-29 2007-09-26 GEMISCHTE ORL1/µ -AGONISTEN ZUR BEHANDLUNG VON SCHMERZ
PCT/EP2007/008379 WO2008040481A1 (de) 2006-09-29 2007-09-26 GEMISCHTE ORL1/μ-AGONISTEN ZUR BEHANDLUNG VON SCHMERZ

Publications (1)

Publication Number Publication Date
PL2081571T3 true PL2081571T3 (pl) 2011-02-28

Family

ID=38982475

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10003202T PL2206498T3 (pl) 2006-09-29 2007-09-26 Mieszani agoniści ORL1/µ do leczenia bólu
PL07818462T PL2081571T3 (pl) 2006-09-29 2007-09-26 Mieszane substancje antagonistyczne ORL 1/µ do zwalczania bólów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10003202T PL2206498T3 (pl) 2006-09-29 2007-09-26 Mieszani agoniści ORL1/µ do leczenia bólu

Country Status (13)

Country Link
US (3) US20080125475A1 (pl)
EP (2) EP2206498B9 (pl)
JP (2) JP5203373B2 (pl)
AT (2) ATE478667T1 (pl)
CA (1) CA2664702C (pl)
CY (2) CY1110879T1 (pl)
DE (2) DE102006046745A1 (pl)
DK (2) DK2206498T3 (pl)
ES (2) ES2351528T3 (pl)
PL (2) PL2206498T3 (pl)
PT (2) PT2206498E (pl)
SI (2) SI2081571T1 (pl)
WO (1) WO2008040481A1 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102007009319A1 (de) * 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
JP5542119B2 (ja) 2008-03-27 2014-07-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング スピロ（５．５）ウンデカン誘導体
KR20120075500A (ko) 2008-03-27 2012-07-06 그뤼넨탈 게엠베하 치환된 4-아미노사이클로헥산 유도체
HRP20140650T1 (hr) 2008-03-27 2014-09-26 Grünenthal GmbH Hidroksimetilcikloheksilamini
CL2009000731A1 (es) 2008-03-27 2009-05-15 Gruenenthal Gmbh Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.
EP2260022B1 (de) 2008-03-27 2017-01-04 Grünenthal GmbH Substituierte cyclohexyldiamine
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
DE102009041581B4 (de) 2009-09-15 2011-09-29 Airbus Operations Gmbh Vorrichtung zur Abgrenzung eines Crew-Ruhebereichs und Verfahren zur Inbetriebnahme einer derartigen Vorrichtung
TWI582092B (zh) * 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
RU2589831C2 (ru) * 2010-08-04 2016-07-10 Грюненталь Гмбх ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН
EP3459533A1 (en) * 2010-08-04 2019-03-27 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
KR101828768B1 (ko) 2010-08-04 2018-02-13 그뤼넨탈 게엠베하 ６’­플루오로­（Ｎ­메틸­ 또는 Ｎ，Ｎ­디메틸­）­４­페닐­４’，９’­디하이드로­３’Ｈ­스피로［사이클로헥산­１，１’­피라노［３，４，ｂ］인돌］­４­아민을 포함하는 약제학적 투여형
AR082559A1 (es) * 2010-08-04 2012-12-19 Gruenenthal Gmbh Forma de dosificacion farmaceutica que comprende 6’-fluoro-(n-metil- o n,n-dimetil)-4’-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan-1,1’-pirano[3,4,b]indol]-4-amina
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8614245B2 (en) 2011-07-08 2013-12-24 Gruenenthal Gmbh Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
US8618156B2 (en) 2011-07-08 2013-12-31 Gruenenthal Gmbh Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
AR089144A1 (es) 2011-12-12 2014-07-30 Gruenenthal Gmbh Formas solidas de (1r,4r)-6-fluoro-(n,n-dimetil)-4-fenil-4,9-dihidro-3h-espiro-[ciclohexano-1,1-pirano-[3,4-b]indol]-4-amina y acido sulfurico
HUE029070T2 (en) 2011-12-12 2017-02-28 Gruenenthal Gmbh (1R, 4R) -6'-Fluoro (N, N-Dimethyl- and N-methyl) -4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'- pyrano- [3,4, B] indole] -4-amine
BR112014014202A2 (pt) 2011-12-12 2017-06-13 Gruenenthal Gmbh formas sólidas de cloridrato de (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-espiro-[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
ES2663412T3 (es) 2012-01-31 2018-04-12 Grünenthal GmbH Parche farmacéutico para la administración transdérmica de (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4-b]indol]-4-amina
LT2809320T (lt) * 2012-02-03 2017-05-25 Grünenthal GmbH (1r,4r)-6`-fluor-(n-metil- arba n,n-dimetil-)-4-fenil-4`,9`-dihidro-3`h-spiro-[cikloheksan-1,1`-pirano[3,4,b]indol]-4-aminas fibromialgijos ir lėtinio nuovargio sindromo gydymui
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320729B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9358022B2 (en) 2012-05-21 2016-06-07 Noha, Llc Clot removal device and method of using same
HUE040039T2 (hu) 2014-02-27 2019-02-28 Gruenenthal Gmbh Az 5-fluor-triptofol elõállítására szolgáló eljárás
CN107427493A (zh) 2015-01-23 2017-12-01 格吕伦塔尔有限公司 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol
MX2018010367A (es) 2016-02-29 2018-12-10 Guenenthal Gmbh Titulacion de cebranopadol.
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
CN122458986A (zh) 2023-02-15 2026-07-24 艾德神经立治疗公司 有用于缓解疼痛的方案和组合物
WO2026035694A1 (en) 2024-08-05 2026-02-12 Adneuris Therapeutics, Inc. Cebranopadol useful for preventing or reducing opioid induced respiratory depression
WO2026161433A1 (en) 2025-01-21 2026-07-30 Adneuris Therapeutics, Inc. Cebranopadol useful for alleviating pain
WO2026161842A1 (en) 2025-01-27 2026-07-30 Adneuris Therapeutics, Inc. Cebranopadol useful for treating pain
CN121471228B (zh) * 2025-11-18 2026-04-21 安徽益普克医药科技发展有限公司 一种化合物及其制备方法与用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
EP1086101B1 (en) * 1998-06-12 2002-12-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Beta-carboline compounds
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
EP0997464B1 (en) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
JP2003524634A (ja) * 1999-12-06 2003-08-19 ユーロ−セルティーク，エス．エイ． ノシセプチン受容体親和性を有するベンズイミダゾール化合物
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
CN1507448A (zh) * 2001-03-02 2004-06-23 ���ŷ� N-丁-3-烯基降丁丙诺啡及其作为止痛药的用途
AR037211A1 (es) * 2001-11-07 2004-10-27 Schering Corp Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE50306277D1 (de) * 2002-11-12 2007-02-22 Gruenenthal Gmbh 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
TW200526668A (en) * 2003-10-02 2005-08-16 Salmedix Inc Substituted indole derivatives
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2005314347A (ja) * 2004-04-30 2005-11-10 Japan Tobacco Inc 疼痛抑制剤
DE102004023635A1 (de) * 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz

Also Published As

Publication number Publication date
PT2081571E (pt) 2010-11-29
CY1110879T1 (el) 2015-06-10
US20080125475A1 (en) 2008-05-29
JP5203373B2 (ja) 2013-06-05
DE102006046745A1 (de) 2008-04-03
EP2206498A1 (de) 2010-07-14
EP2081571A1 (de) 2009-07-29
PL2206498T3 (pl) 2012-04-30
DE502007004875D1 (de) 2010-10-07
CA2664702A1 (en) 2008-04-10
PT2206498E (pt) 2012-02-15
DK2206498T3 (da) 2012-03-19
SI2206498T1 (sl) 2012-03-30
SI2081571T1 (sl) 2010-12-31
JP2013116907A (ja) 2013-06-13
ATE542532T1 (de) 2012-02-15
ES2377482T3 (es) 2012-03-28
ES2351528T3 (es) 2011-02-07
ATE478667T1 (de) 2010-09-15
CA2664702C (en) 2016-08-09
JP5698282B2 (ja) 2015-04-08
EP2206498B1 (de) 2012-01-25
US20110015220A1 (en) 2011-01-20
JP2010504926A (ja) 2010-02-18
WO2008040481A1 (de) 2008-04-10
EP2081571B1 (de) 2010-08-25
EP2206498B9 (de) 2012-04-18
DK2081571T3 (da) 2010-11-08
CY1112471T1 (el) 2015-12-09
US20150342929A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
SI2081571T1 (sl) Mešani ORL 1/u agonisti za zdravljenje bolečine
RU2492858C2 (ru) Композиции и способы профилактики и лечения зависимостей
Zislis et al. Effects of the CRF receptor antagonist d-Phe CRF (12–41) and the α2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats
JP2010537990A (ja) アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ
Greenwell et al. The α1 adrenergic receptor antagonist prazosin reduces heroin self-administration in rats with extended access to heroin administration
Emery et al. Drug-specific differences in the ability of opioids to manage burn pain
NO20150971L (no) Alfa-aminoamidderivater nyttige i behandlingen av addiktive forstyrrelser
Leri et al. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats
Getsy et al. D-cysteine ethyl ester reverses the deleterious effects of morphine on breathing and arterial blood–gas chemistry in freely-moving rats
Gregoretti et al. Clonidine in perioperative medicine and intensive care unit: more than an anti-hypertensive drug
Sorge et al. The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration
Lehmann Opioids: overview on action, interaction and toxicity
WO2008066603A3 (en) S-nitrosothiol compounds and related derivatives
Gengo et al. DPI-3290 [(+)-3-((α-R)-α-((2 S, 5 R)-4-Allyl-2, 5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A Mixed Opioid Agonist with Potent Antinociceptive Activity and Limited Effects on Respiratory Function
Loots et al. Agents for sedation in ophthalmic surgery: a review of the pharmacodynamics and clinical applications
US20050101621A1 (en) Method for rapid detoxification of addiction
AU2013201888B2 (en) Compositions and methods for prophylaxis and treatment of addictions
O'Brien Evidence-based treatments of addiction.
Mokler et al. Effects Of Combined Opioids On Pain And Mood In Mammals
HK1227631A1 (en) Compositions and methods for prophylaxis and treatment of addictions
CA2540190A1 (en) Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders